Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ACERW ALERT ???AWAITING FDA.APPROVAL, which I assume will happen we fly, only .05 cents now can head up to $.50 If PR comes out$$$BUY BUY ACERW
Stock and warrant are converting. Warrant new ticker is ACERW
Sorry I mean opxa
Why this goes down when Ipca is up??
How about in the .05's do you know what will be of the warrants ?
Nothing but down on this pos
Ah never mind that then lol, figured it gets pumped every so often
Not really r/s coming as per merger agreement .. :/
Nope Canada! OPXAW is overdue for a pop. It will come
Wishmaster u from stl?
Looks like a nice bounce, may go hard second half of the day
Or this week, sudden volume spike again off lows looks ready to get back in the teens ahead again IMO.
I think it might today
OPXAW setting up for another round into the teens off recent lows?
OPXA will reach $3 easy OPXAW will go thru the roof once OPXA passes $1.50
What is the point? Selling so cheap
Why is it going down? I know that this has a PT of $2.00 for next month
Yeah, I figured that out couple minutes after my post. What a bad pumper.
He was talking about last Monday
OPXAW Please review 10Q released on May 12, 2017. This does NOT read like general disclosure of Going Concern to me! Thoughts please?
Note 1. Basis of Presentation and Going Concern
The accompanying interim unaudited consolidated financial statements of Opexa Therapeutics, Inc. (“Opexa” or the “Company”), have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited financial statements and notes thereto contained in Opexa’s latest Annual Report filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the consolidated financial statements that would substantially duplicate the disclosure contained in the audited consolidated financial statements for the most recent fiscal year as reported in Form 10-K have been omitted.
The accompanying consolidated financial statements include the accounts of Opexa and its wholly owned subsidiary, Opexa Hong Kong Limited (“Opexa Hong Kong”). All intercompany balances and transactions have been eliminated in the consolidation.
Going Concern. The accompanying interim unaudited consolidated financial statements for the three months ended March 31, 2017 have been prepared assuming that the Company will continue as a going concern, meaning the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations. As of March 31, 2017, the Company had cash and cash equivalents of $2.8 million as well as accounts payable, short-term notes payable and accrued expenses aggregating $818,315. While the Company has historically recognized revenue related to certain upfront payments received from Ares Trading SA (“Merck Serono”), a wholly owned subsidiary of Merck Serono S.A., in connection with the Option and License Agreement and an amendment thereto between Merck Serono and the Company, the Company has never generated any commercial revenues, nor does it expect to generate any commercial revenues for the foreseeable future or other revenues in the near term that will result in cash receipts. Opexa continues to incur net losses, negative operating cash flows and has an accumulated deficit of approximately $162.2 million as of March 31, 2017. These factors raise substantial doubt as to the Company's ability to continue as a going concern.
Following the October 28, 2016 announcement that the Abili-T trial did not meet its primary or secondary endpoints, and in order to conserve cash resources while it reevaluated its programs and explored various strategic alternatives, during the fourth quarter of 2016 and first quarter of 2017 the Company implemented several reductions in workforce totaling 90% of its then 20 full-time employees. As of March 31, 2017 Opexa has two full-time employees. After further analysis of the data from the Abili-T trial, the Company has determined that it will not move forward with further studies of Tcelna in SPMS at this time and is conducting a review of its other research and development programs, including the preclinical program for OPX-212 in NMO, to assess the viability of continuing to pursue one or more of these programs. The Company is also exploring its strategic alternatives. The Company cannot fully predict its future cash needs until it completes this analysis. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
The Company continues to explore potential opportunities and alternatives to obtain the additional resources that will be necessary to support its ongoing operations through and beyond the next 12 months, including raising additional capital through either private or public equity or debt financing as well as using its at-the-market offering program and cutting expenses where possible. However, in light of the disappointing Abili-T study results, there can be no assurance that the Company will be able to secure additional funds or, if such funds are available, whether the terms or conditions would be acceptable to the Company.
What did you hear ? What's coming monday ? Just bought 60k shares today at 0,1125
well it was your claim but now not sure on what basis you made that claim.
questions, shouldn't OPXAW move with correlation to OPXA since its just a warrant? If OPXA is up 3% how come W is negative?
Good. Maybe you'll have to wait your whole life.
Still waiting on that .60 and PR....
Thank god it bounce off that level, am still holding from that same level. Not a short lol
LOD was .12, nice try though
Ohh man seems like closing at LOD imo
I bought OPXAW and not OPXA...What is the difference? What did I buy
One would think an update was coming with this kind of price jump in 24 hrs.
No clue and yes agreed. Still holding great gains
So PR is speculation ? Either way it was a nice run ...
was wondering the same ...
How long has this had a W? How much longer until removed? What happens after that?
When is that .60 and PR coming...?
Flippers paradise right now
Not happening today though...
Yes, and when does it is going to rocket north fast!
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
140
|
Created
|
06/05/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |